Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?

Simply Wall St.08-19

Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier. See...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660444987?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-19 17:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660444987","market":"sg","top_or_hot":-1,"title":"Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?","media":"Simply Wall St.","content":"<div>\n<p>Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-19 17:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEMS","symbol_name":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea","article_id":"2660444987","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660444987","pubTimestamp":1787131188,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier.\nSee our latest analysis for Legend Biotech.\nLegend Biotech’s latest earnings and leadership change in July have come against a mixed share price backdrop, with a 1-year total shareholder return that declined 38.5% and a 3-year total shareholder return that declined 68.3%. Meanwhile, the year-to-date...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","MEDI":"HARBOR HEALTH CARE ETF","BK4588":"碎股","CANC":"TEMA ONCOLOGY ETF","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4581":"高盛持仓","LEGN":"传奇生物","XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念"},"translate_title":"Legend Biotech (LEGN) 第二季度扭亏为盈，股价便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1.5,"MEMS":0.6,"CANC":0.6,"XBI":1.5,"MEDI":0.6},"content_text":"Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier. See our latest analysis for Legend Biotech. Legend Biotech’s latest earnings and leadership change in July have come against a mixed share price backdrop, with a 1-year total shareholder return that declined 38.5% and a 3-year total shareholder return that declined 68.3%. Meanwhile, the year-to-date share price return is up 1.9%, hinting at early signs of stabilising momentum after a tougher multi year period. If you are looking beyond Legend Biotech for other potential ideas in this area, now could be a good time to review a curated list of healthcare focused AI opportunities through the 42 healthcare AI stocks Legend Biotech has shifted from losses to quarterly profit while the share price is still well below past levels. Does that mismatch leave more upside for new buyers, or does recent strength already capture the turnaround story? AdvertisementMost Popular Narrative: 59.6% Undervalued The most followed narrative on Legend Biotech pegs fair value at $54.23, compared with the last close at $21.92. That gap reflects a view that the current share price does not fully reflect the company’s projected revenue, earnings, and margin path.  Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.  Read the complete narrative. Curious what kind of revenue ramp, margin shift, and future earnings multiple are baked into that $54.23 figure. The narrative ties together growth in multiple myeloma, expansion into new geographies, and a specific profit profile to arrive at its fair value path. Result: Fair Value of $54.23 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Legend Biotech’s reliance on CARVYKTI, along with the potential for rising competition or pricing pressure, could quickly challenge the upside case that many analysts are leaning on. Find out about the key risks to this Legend Biotech narrative. Next Steps With both risks and rewards in play for Legend Biotech, it makes sense to move quickly and test the narrative against the underlying data yourself. To weigh those red flags against the potential upside in a single view, start with the 4 key rewards and 1 important warning sign. Looking for more investment ideas beyond Legend Biotech? If Legend Biotech has sharpened your interest, do not stop here. Use the Simply Wall Street screener to uncover other stocks that match your approach.  Target reliable cash generators by checking companies that pass the solid balance sheet and fundamentals stocks screener (50 results) and may better align with your comfort on financial strength. Hunt for potential value opportunities using the screener containing 20 high quality undiscovered gems before they appear on everyone else’s radar. Prioritise capital preservation and steadier price moves by reviewing the 79 resilient stocks with low risk scores that could fit a more cautious portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660444987","isCrawlerRequest":true}